摘要
目的探讨去甲氧柔红霉素联用阿糖胞苷方案治疗难治复发性急性粒细胞白血病(即AML)的临床疗效。方法选取我院收治的188例难治复发性AML患者为研究对象,分为研究组94例(去甲氧柔红霉素+阿糖胞苷)和对照组94例(柔红霉素+阿糖胞苷),跟踪随访,比较两组预后效果。结果研究组总有效率、生存期限均优于对照组,并且不良反应率低于对照组,P<0.05。结论去甲氧柔红霉素联用阿糖胞苷能够有效控制难治复发性AML的病情,延长生存时间。
Objective To discuss the effect of idarubicin and cytarabine combined method for the treatment of refractory and relapsed acute myelogenous leukemia（AML）. Methods 188 cases with relapsed acute myelogenous leukemia were selected as the research cases in our hospital. They were randomly divided into study group（idarubicin combined with cytarabine,n=94） and control group（daunorubicin and cytarabine,n=94）,a follow-up was made and the curative effect was compared between the two groups. Results In the study group,the total efficiency and survival period were significantly better than the control group,and the adverse reaction rate was significantly lower than the control group,P 0.05. Conclusion Idarubicin combined with cytarabine can effectively control the refractory and relapsed AML and prolong the survival time.
出处
《中国卫生标准管理》
2016年第4期94-95,共2页
China Health Standard Management
